Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Granted US Patent Supporting Vasclir Diagnostic; Begins Intended-Use Study for Test

Premium

Vermillion announced this week it has been granted a US patent allowing it to use B2-microglobulin as a biomarker for its peripheral artery disease diagnostic Vasclir and that it has begun an intended-use population study for the test.

The patent, number 7,867,719, covers "biomarker combinations that include B2-microglobulin for the diagnosis and management of peripheral artery disease and to the measurement of the biomarkers by a variety of methods, including mass spectrometry and immunoassay," the company said in a statement.

Also in the statement, CEO Gail Page said that Vermillion continues "to progress in our PAD program, including the initiation of our intended-use study."

The granting of the patent follows on the notice of allowance for it that Vermillion received in September (PM 9/17/2010).

Vasclir is the second test Quest Diagnostics accepted from the company as part of the partners' three-test strategic alliance agreement. The first was the ovarian cancer assay OVA1.

During the company's second-quarter earnings call in August, chief science officer Eric Fung said developing Vasclir is one of Vermillion's primary R&D focuses, and noted the firm planned to begin an intended-use population study for the test by the end of 2010 (PM 08/13/2010).

According to Fung, PAD currently affects some 12 million Americans, a number that is expected to rise as the incidence of diabetes increases.

During the August earnings call, Page said that a commercial launch of Vasclir is likely still several years away.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.